BeiGene (BGNE +1.4%) and Boehringer Ingelheim Biopharmaceuticals ink an agreement under which BI will manufacture BeiGene's PD-1 inhibitor tislelizumab at its Shanghai facility as part of a Marketing Authorization Holder trial project pioneered by the two firms. Heretofore, BI has supplied product for its clinical trials.
Under the terms of the agreement, BI will manufacture tislelizumab in China on an exclusive basis for a multiyear term with contract extension possible. BeiGene has certain preferred rights for future capacity expansion by BI in China.
Financial terms are not disclosed.
Subscribe for full text news in your inbox